Abstract Luteolin (LUT), a flavonoid compound widely presenting in natural plants, has been extensively studied for its diverse biological properties, involving anti-inflammatory, antioxidant, anti-apoptosis and other properties. The aim of this study was to investigate the effect of LUT on lipopolysaccharide (LPS)-induced IPEC-J2 cell damage and its underlying mechanism. Results showed that LPS treatment induced injury in IPEC-J2 cells, leading to tight junction disruption, ROS accumulation, and cell apoptosis. Remarkably, LUT attenuated LPS-induced IPEC-J2 cells damage by the up-regulation of ZO-1, Occludin, and Claudin-1 protein expression levels. Besides, LUT increased the activities of CAT, and SOD and prevented LPS-induced MDA and ROS production. LUT suppressed NF-κB activation in LPS-induced IPEC-J2 cells, reducing IL-1β, IL-6 and TNF-α expression. Moreover, LUT attenuated LPS-induced apoptosis in IPEC-J2 cells by up-regulating expression of Bcl-2 and down-regulating expression of Caspase-3, Caspase-9 and Bax. Furthermore, LUT upregulated AMPK/ULK signaling pathway and Parkin/PINK1 mediated-mitophagy in dose-dependent manner. While knockdown of AMPK by short-hairpin RNA (shRNA) weakens the protect effects of LUT against LPS-induced IPEC-J2 cells damage, as evidenced by the accumulation of excessive ROS and impaired mitophagy. In summary, LUT exhibits the ability to protect against LPS-induced damage to intestinal tight junctions by enhancing mitophagy through via AMPK activation.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: